Controlled release system for pulmonary delivery of surfactant protein d

Abstract

A controlled release system including surfactant protein D (SPD) and a carrier suitable for controlled release that can be polylactic-co-glycolic acid (PLGA). The system can be in the form of a nanoparticle. A pharmaceutical composition including the system and a pharmaceutically acceptable carrier. Methods of treatment of a disease, disorder or condition associated with a decreased level of SPD in a subject, or for pulmonary delivery of SPD, include administering the pharmaceutical composition to a subject in need of such treatment.

What is claimed is: 
     
         1 . A controlled release system comprising a nanoparticle or a microparticle, wherein said nanoparticle or microparticle comprises surfactant protein D (SPD) as the active agent, and a polymeric carrier suitable for controlled release of the SPD, wherein said system does not comprise surfactant components other than the SPD. 
     
     
         2 . The system according to  claim 1 , wherein said polymer carrier is selected from the group consisting of polylactic-co-glycolic acid (PLGA), polylactic acid (PLA), polyglycolic acid (PGA), chitosan, gelatin, polycaprolactone, and poly-alkyl-cyanoacrylates. 
     
     
         3 . The system according to  claim 2 , wherein said polymer carrier is polylactic-co-glycolic acid (PLGA). 
     
     
         4 . The system according to  claim 3 , wherein a ratio of lactic acid to glycolic acid in said PLGA is selected from the group consisting of 50:50, 65:35, 70:30, 75:25, 82:18 and 85:15. 
     
     
         5 . The system according to  claim 4 , wherein an average radius of said nanoparticle is selected from the group consisting of between about 20 and about 300, between about 50 and about 150 nm, and about 100 nm. 
     
     
         6 . The system according to  claim 1 , further comprising a pharmaceutically acceptable carrier. 
     
     
         7 . The system according to  claim 1 , wherein said system is an aerosol. 
     
     
         8 . The system according to  claim 1 , wherein the SPD is the sole active agent in the nanoparticle or microparticle. 
     
     
         9 . A method for treating a disease, disorder or condition selected from the group consisting of chronic obstructive lung disease (COPD), asthma, acute bronchitis, chronic bronchitis, bronchopulmonary dysplasia, emphysema, infant respiratory distress syndrome (IRDS), acute respiratory distress syndrome (ARDS), lung infections, persistent pulmonary hypertension, lung hypoplasia, cancer, cystic fibrosis, alveolar proteinosis, upper respiratory inflammation, congenital SP-B deficiency, respiratory syncytial virus (RSV), allergic rhinitis, influenza, and a disease, disorder or condition associated with a decreased level of SPD in a subject in need thereof, comprising administering the system according to  claim 1  to said subject. 
     
     
         10 . A method for pulmonary delivery of SPD comprising administering to a subject in need thereof the system according to  claim 1 .